Lightstone Ventures, a bi-coastal venture capital firm focused on the life sciences, said Tuesday it has raised another $375 million to invest in early-stage companies.
Lilly Announces Agreement to Acquire Disarm Therapeutics
Eli Lilly is snapping up a little Cambridge-based biotech to add to their neuro group.